NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript
Operator: Greetings and welcome to the NeoGenomics First Quarter 2025 Conference Call.
Neogenomics Inc (NEO)
Market is closed
Sector: Services-Testing Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Royce & Associates Chuck Royce | 858,046 | $8,142,857 | +27% | 0.09% |
| 2. | Bailard Inc Thomas Bailard | 19,300 | $183,157 | 0% | |
| 3. | Neo Ivy Capital Renee Yao | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.88 | 18,900 | Officer, Director | 18,900 | 2025-05-06 | Filing | |
| $7.63 | 10,000 | Director | 10,000 | 2025-05-05 | Filing | |
| $7.76 | 4,510 | Director | 15,846 | 2025-05-05 | Filing | |
| $7.51 | 20,000 | Officer | 158,494 | 2025-05-02 | Filing | |
| $30.63 | 17,000 | Officer, Director | 72,736 | 2021-12-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.36 | 5,175 | Officer | 37,129 | 2024-11-15 | Filing | |
| $16.05 | 1,040 | Officer | 43,813 | 2024-08-15 | Filing | |
| $15.74 | 1,049 | Officer | 44,867 | 2024-05-15 | Filing | |
| $15.97 | 6,112 | Director | 50,062 | 2024-03-04 | Filing | |
| $14.96 | 2,587 | Officer | 34,866 | 2024-02-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,864,426 | $188,513,400 | 0% | |
| 2. | 3,871,964 | $36,744,936 | 0.05% | |
| 3. | 34,405,000 | $29,758,261 | 0.13% | |
| 4. | 2,350,746 | $22,308,580 | 0.34% | |
| 5. | 1,527,267 | $14,493,762 | 0.01% |
News See All
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Second Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
20 Most Profitable Stocks of the Last 20 Years
The stock market has a long history of generating wealth for investors. While past performance doesn't guarantee future results, studying successful companies can provide valuable insights.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.01.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the NeoGenomics Third Quarter 2023 Earnings Call -- Third Quarter 2023 Financial Results Conference Call and Webcast.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2023 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.